An interventional study of Sleep hygiene education and Cognitive behavioural therapy for insomnia (CBTi) in Insomnia and Breast Cancer Metastatic Breast Cancer, sponsored by University of Strathclyde. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Strathclyde · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Sleep Initiation and Maintenance Disorders with a site in United Kingdom — 11 open to participants now, 13 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · United Kingdom.
Among the 59 studies in Sleep Initiation and Maintenance Disorders with a site in United Kingdom, this one is the 26th largest by planned enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2026, is one of 31 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 58th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →11 of the 59 studies in Sleep Initiation and Maintenance Disorders with a site in United Kingdom are open now. Recruiting first, the newest first:
Sheffield Children's NHS Foundation Trust · Sites in United Kingdom
Ages 6–16
University of Oxford · Sites in United Kingdom
Ages 18+
Leeds Beckett University · Sites in United Kingdom
Ages 40–60 · Women only · Healthy volunteers
Vanda Pharmaceuticals · Sites in United Kingdom, United States, Germany and 1 more country
Ages 2–17
University of Westminster · Sites in United Kingdom
Ages 18–50 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 52 across the 49 interventional studies, 200 across the 7 observational. Of the 39 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 59 have an industry lead sponsor. The 10 most frequent:
University of Strathclyde is the lead sponsor of 20 studies on the registry; 10 are open to participants now.
University of Strathclyde has 3 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Sleep Initiation and Maintenance Disorders with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953869Phase 3Vanda PharmaceuticalsEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | 2027-11 |
| NCT07754981University of SheffieldSelf-Help Booklets for Sleep in Adults With Pulmonary Hypertension | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Sleep Initiation and Maintenance Disorders with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate an intervention designed to improve insomnia and sleep in people living with secondary breast cancer. The study will assess whether the intervention is feasible and acceptable to deliver and participate in, and whether it may improve sleep and related outcomes.
The main questions the study aims to answer are:
Participants will be allocated to one of two groups:
Participants will complete questionnaires, sleep diaries, and sleep monitoring using a wearable device at three time points: before treatment, immediately after the five-week treatment period, and three months after treatment.
Participants will also be invited to provide feedback about their experiences of taking part in the study and the intervention through either an interview or survey.
The results will be used to determine whether the intervention is feasible and acceptable and whether there is evidence of potential benefits for sleep and other outcomes. The findings will help determine whether further research of the intervention is warranted and if there is further intervention development work required.
The primary aim of this project is to explore the feasibility and acceptability of a newly developed insomnia intervention based on Cognitive Behavioural Therapy for Insomnia (CBTi). CBTi is recommended as the gold standard treatment for insomnia (NICE, 2021). CBTi combines cognitive, behavioural, and educational strategies to improve sleep and can be tailored to individual needs. Feasibility outcomes will be assess including participant recruitment and retention rates, intervention fidelity, completion of outcome measures, and participant acceptability. The secondary aim is to investigate the preliminary effectiveness of the intervention compared with a sleep hygiene education (SHE) control group. Preliminary effectiveness outcomes will include changes in sleep, mental health, quality of life, and daily functioning.
The aim is to recruit 50 adults with secondary breast cancer who meet the screening criteria for insomnia disorder, based on a Sleep Condition Indicator (SCI) score of \<16. Individuals will not be eligible if they are experiencing current suicidal ideation, recently completed psychological treatment for insomnia, have a prognosis of \<6 months or experience severe pain that is poorly controlled. The investigators will adopt multiple routes to recruitment including direct contact with individuals who previously completed consented to being contacted about future research; via breast cancer specific charities and support organisations and social media, support groups, physical and digital posters, and word-of-mouth.
Participants will access the online form (via Qualtrics) that contains participant information sheet, eligibility screening form, where appropriate, they can complete the consent form and assessment questionnaire. For participants who are eligible and consent to take part, they will be randomly allocated to the intervention or the control group (n=25 in each arm).
After randomisation, participants will be sent an email with a link to complete a baseline (pre-intervention) assessment questionnaire, complete the sleep diary and wear an actigraphy device for 7 days prior to commencement of the treatment phase to record sleep and rest/activity rhythms. Participants in the intervention group will be invited to attend an onboarding session and the 5 weekly sessions. The sessions will be delivered by trained research facilitators in groups of up to 6 participants. The control group will be provided with the SHE resources and advised to put the changes in place over the subsequent 5-week period.
Two-weeks following the final session, and 3 months following the final session, all participants will be invited to complete the same questionnaires as during the baseline assessment, sleep diary and actigraphy device. Participants will be invited to participate in a semi-structured interview with the researcher, or to provide feedback via an online survey.
Interventions - Sleep hygiene education (SHE) will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Participants in the SHE condition will be instructed to implement the SHE advice over a 5-week period. SHE has successfully been used as a control condition in other trials evaluating CBTi and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to CBTi.
ESTABLISH better sleep- The intervention was developed by behavioural sleep medicine experts at the Strathclyde Sleep Centre in collaboration with key stakeholders, including individuals living with secondary breast cancer and healthcare professionals. Intervention development involved a co-production study consisting of three iterative workshops exploring preferred methods of delivery, adaptations to treatment components, and potential barriers and facilitators to implementation. The newly developed protocol was shared with stakeholders for feedback and piloted with 4 patient participants. This resulted in final refinements. The intervention is based on the core components of Cognitive Behavioural Therapy for Insomnia (CBTi), targeting the sleep-related behaviours and thoughts that contribute to the development and maintenance of insomnia. Components include sleep education and sleep hygiene, Sleep Restriction Therapy (SRT, referred to in this programme as sleep optimisation therapy), Stimulus Control, relaxation strategies, and cognitive techniques. The intervention has been specifically adapted for individuals living with secondary breast cancer. Key adaptations include a comprehensive assessment to consider condition, co-morbidities and treatment-related impacts and tailor content specifically to individual needs; additional content relating to fatigue management; monitoring of key symptoms including fatigue and pain; scheduled napping guidelines, and inclusion of relevant examples throughout. For sleep restriction therapy specifically, a minimum time in bed of 6 hours was selected to account for additional sleep need and treatment related side-effects. For titration of SRT, an 85% sleep efficiency threshold was considered optimal to increase the sleep window given potential need for extended time in bed. The intervention will be delivered in weekly group sessions, either online via videoconferencing software or in person at the University of Strathclyde. Groups will include up to 6 participants. The intervention programme will include: an onboarding session lasting approximately 20-30 minutes, 5 weekly treatment sessions, optional facilitator check-in at week 3, and home-based practice of behavioural techniques between sessions. Intervention materials will include PowerPoint presentations, participant workbooks, facilitator manuals, videos, and supporting resources for family members and healthcare professionals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm will act as a control group with sleep hygiene education (SHE) + treatment as usual (TAU).
Behavioral: Sleep hygiene education
This arm will be the intervention group with cognitive behavioural therapy for insomnia (CBTi) + sleep hygiene education (SHE) + treatment as usual (TAU).
Behavioral: Cognitive behavioural therapy for insomnia (CBTi)
Participants in this group will receive a sleep hygiene education resource containing evidence-based advice regarding sleep habits, lifestyle factors, and sleep environment recommendations. Participants in the control condition will be asked to implement the advice over a 5-week period and will continue to complete sleep diaries, actigraphy monitoring, and outcome assessments at the same time points as the intervention group.
Also known as: Sleep education
The intervention was developed by behavioural sleep medicine experts at the Strathclyde Sleep Centre in collaboration with individuals living with secondary breast cancer and healthcare professionals. The intervention is based on the core components of CBTi targeting the sleep-related behaviours and thoughts that contribute to the development and maintenance of insomnia that were specifically adapted for secondary breast cancer patients. Components include sleep education and sleep hygiene, sleep restriction therapy, stimulus control, relaxation strategies, and cognitive techniques. The intervention will be delivered in 5 weekly sessions, by the research team. The intervention programme includes an onboarding session, 4 weekly sessions, an optional individual check-in at week 3 and involved home-based practice of behavioural components.
Participant recruitment
Recruitment feasibility will be assessed using data collected through an online recruitment/sign-up form, which includes the Participant Information Sheet (PIS), eligibility screening questionnaire, informed consent form, and assessment questionnaire. Enrolment data for all participants who provide informed consent will be used to assess feasibility of recruitment. Recruitment will be considered feasible where 80% of target achieved. The form will also record the number of individuals who meet the eligibility criteria but do not enrol in the study after viewing the PIS and completing the screening questionnaire. Where provided, reasons for non-participation will also be recorded. This will allow recruitment rates and reasons for non-participation to be assessed.
Time frame: At completion of the recruitment period (up to 9 months after recruitment initiation)
Participant retention
Retention will be assessed by determining the proportion of enrolled participants who remain in the study and complete all outcome assessments throughout the study period. A retention rate of at least 70% of enrolled participants will be considered the target.
Time frame: At 3-month follow-up
Intervention fidelity - facilitator
Intervention fidelity will be assessed by examining facilitator adherence to the intervention protocol using a check-list. Facilitator adherence will be assessed in sampled sessions, with adherence defined as delivery of \>80% of the specified intervention content.
Time frame: 1 year study period
Intervention fidelity - participants
Participant engagement in the intervention group will be assessed by attendance at ≥2 of 4 intervention sessions (or review of session recordings) in the intervention group.
Time frame: During the intervention phase through immediately post-intervention
Outcome measure completion
The aim of this study is to determine the feasibility of conducting a definitive randomised controlled trial. Therefore, this outcome will assess the feasibility of the outcome measures. Success will be defines as \>70% of questionnaires and sleep diaries completed.
Time frame: From baseline through 3-month follow-up
Acceptability of the intervention
Acceptability will be assessed through participant interviews and/or a feedback survey. The interview schedule and survey will assess seven components of intervention acceptability: affective attitude, burden, ethicality, intervention coherence, opportunity costs, perceived effectiveness, and self-efficacy. Interviews will likely include \>15 participants from the intervention group and \>5 from the SHE control. The remaining participants will be invited to provide feedback via a survey.
Time frame: 2-4 weeks post-intervention
Change in insomnia severity
Insomnia Severity Index (ISI, Morin et al., 2011). The ISI is a 7-item measure that evaluates the severity of sleep disturbance during the past 2 weeks. Scores range from 0-21 with higher scores indicating greater insomnia severity.
Time frame: Baseline, immediately post-intervention, and 3-month follow-up
Change in sleep outcomes
Data from sleep diaries and actigraphy.
Time frame: Baseline, immediately post-intervention, and 3-month follow-up
Change in mental health [depression]
Patient Health Questionnaire 9 (PHQ-9). The PHQ-9 (Kroenke, Spitzer \& Williams, 2001) is a 9-item validated measure for the use of identifying symptoms of depression based on the DSM-5 criteria. Scores range from 0-27, with a higher score indicating more severe depressive symptoms
Time frame: Baseline, immediately post-intervention, and 3-month follow-up
Change in mental health [anxiety]
Generalised Anxiety Disorders - 7 (GAD-7). The GAD-7 (Spitzer, Kroenke \& Williams, 2006) is a 7-item which measures the presence and severity of anxiety symptoms with the use of some DSM-5 criteria for Generalised Anxiety Disorder. Scores range from 0-21, with a higher score indicating more severe anxiety symptoms.
Time frame: Baseline, immediately post-intervention, and 3-month follow-up
Change in fatigue
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue). This is a 13-item questionnaire measuring self-reported fatigue and its impact on daily activities and function. Each item is scored on a 5-point Likert-scale and scores range from 0 to 52, with lower scores indicating greater fatigue
Time frame: Baseline, immediately post-intervention, and 3-month follow-up
Change in Quality of Life
Functional Assessment of Cancer Therapy - Breast (FACT-B scale). The FACT-B (Hahn et al., 2015) is a questionnaire designed to asses quality of life in individuals with breast cancer. It is a 37-item measure with five subscales to evaluate wellbeing across the following domains physical, social, emotional, functional wellbeing, as well as additional breast-cancer specific items. Each item is scored on a 5 point Likert Scale (0 = not at all, 4 = very much), with total scores ranging from 0-148, and higher scores indicate better quality of life
Time frame: Baseline, immediately post-intervention, and 3-month follow-up
Plan to share: No — Individual participant-level data will not be shared with other researchers. Due to the small and specific participant population, sharing individual-level data may increase the risk of participant identification. Data will therefore be retained and managed in accordance with applicable ethical, confidentiality, and data protection requirements. Anonymised and/or aggregated data from the outcome measures may be made available to other researchers where appropriate, if this does not compromise participant confidentiality or allow individuals to be identified.
Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.
Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 15 months is close to that.
Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
University of Strathclyde